Table 4.
Vaccine Poliovirus Shedding within 42 Days of Oral Polio Vaccine Receipt by Polio Seroconversion and Human Immunodeficiency Virus Status
| Serotype | HIV Status | Seroconverted | No Seroconversion |
|---|---|---|---|
| 1 | HIV+ | 33% (5/15) | 31% (5/16) |
| HIV− | 0% (0/19) | 9% (1/11) | |
| P Value | .01 | .35 | |
| 2 | HIV+ | 38% (6/16) | 33% (5/15) |
| HIV− | 4% (1/24) | 0% (0/6) | |
| P Value | .01 | .26 | |
| 3 | HIV+ | 33% (2/6) | 28% (7/25) |
| HIV− | 0% (0/14) | 0% (0/16) | |
| P Value | .08 | .03 |
Data are from 61 stool samples (31 from human immunodeficiency virus [HIV]–infected, 30 from HIV-uninfected children) that could be linked to seroconversion status and were collected within 42 days of an oral polio vaccine dose.
Abbreivation: HIV, human immunodeficiency virus.